Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
REduced Frequency ImmuNE Checkpoint Inhibition in Cancers
- Status
- UNKNOWN
- Phase
- PHASE2
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
- Status
- RECRUITING
- Phase
- PHASE2
Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)
- Status
- COMPLETED
- Phase
- PHASE2
Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV
- Status
- RECRUITING
- Phase
- PHASE1
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets
- Status
- TERMINATED
- Phase
- PHASE2
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)
- Status
- COMPLETED
- Phase
- PHASE2
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
RegoNivo vs Standard of Care Chemotherapy in AGOC
- Status
- COMPLETED
- Phase
- PHASE3
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
- Status
- UNKNOWN
- Phase
- PHASE2
Pre-operative Immunotherapy in Stage II-III Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2